Female Founder
First-Time FounderActively RaisingAbout
Precision neurology diagnostics company developing AI-powered molecular biomarker tests to predict treatment outcomes for neurological conditions. Starting with ShuntIQ, a biomarker test to predict shunt surgery outcomes for Normal Pressure Hydrocephalus (NPH) patients.
Team
Ghazi
COO and Regulatory
Caleb
Data Analyst
Mariagrazia
CEO
Products
ShuntIQ
AI-powered biomarker test that predicts shunt surgery outcomes for Normal Pressure Hydrocephalus (NPH) patients with over 90% accuracy. Uses 16 metabolites selected by DIMA foundation model from multi-omics dataset to guide clinicians' biology-driven decisions, delivering results in days instead of years. Addresses the critical gap where 80% of NPH patients are misdiagnosed and clinicians lack reliable tools to predict surgical response.
Click to read more
DIMA Platform
Foundation model for molecular biomarker discovery trained on multi-omics and clinical data. Discovers novel biomarkers to predict treatment responses using blood or CSF samples. Platform focuses on metabolites as ideal biomarkers that are easily measurable in biofluids, closely linked to phenotype, and highly biologically interpretable to directly reflect disease activity and therapeutic response.
Click to read more